Recent Finacing
Recent Raise
Shifa Biomedical develops orally bioavailable small‑molecule PCSK9/LDLR antagonists for cardiovascular disease, advancing lead P‑21—discovered via proprietary virtual screening and optimization—through preclinical and IND‑enabling studies.
